Biocardia CEO Peter Altman buys $555 in common stock
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biocardia Inc (BCDA)"Biocardia Inc stock price live, this page displays NASDAQ BCDA stock exchange data. View the BCDA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biocardia Inc real time stock price chart below.
What Is the Biocardia Inc Stock Price Today?
The Biocardia Inc stock price today is 2.170.
What Is the Stock Symbol for Biocardia Inc?
The stock symbol for Biocardia Inc is ""BCDA.""
What Stock Exchange Does Biocardia Inc Trade On?
Biocardia Inc is listed and trades on the NASDAQ stock exchange.
Is Biocardia Inc a Good Stock to Buy?
Determining whether Biocardia Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCDA quote. (ISIN: US09060U6064)"
What Is the Biocardia Inc Stock Price Today?
The Biocardia Inc stock price today is 2.170.
What Is the Stock Symbol for Biocardia Inc?
The stock symbol for Biocardia Inc is ""BCDA.""
What Stock Exchange Does Biocardia Inc Trade On?
Biocardia Inc is listed and trades on the NASDAQ stock exchange.
Is Biocardia Inc a Good Stock to Buy?
Determining whether Biocardia Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BCDA quote. (ISIN: US09060U6064)"
2.170
+0.010(+0.46%)
Closed
After Hours
2.100-0.070(-3.226%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.110
2.200
52 wk Range
1.840
10.790
BCDA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1102.200
52 wk Range
1.84010.790
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCDA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Price Target
25.000
Upside
+1,052.074%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Biocardia Inc Company Profile
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Biocardia Inc SWOT Analysis
CardiAMP's Promise | Explore BioCardia's innovative cell therapy for heart failure, showing potential in reducing cardiac events and improving quality of life for patients |
FDA Backing | Learn how the FDA's protocol amendment expands patient eligibility for CardiAMP HF II trial, potentially accelerating development and improving outcomes |
Financial Boost | Delve into the impact of CMS reimbursement approval on BioCardia's trial costs and development timeline, enhancing the company's financial outlook |
Market Opportunity | Analysts set price targets ranging from $4 to $25, reflecting the potential of BioCardia's therapy in the growing cardiovascular treatment market |
BCDA Full Pro Research
Institutional-Grade Stock Analysis
Understand how BCDA earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Biocardia Inc Earnings Call Summary for Q3/2024
- CardiAMP Heart Failure I trial shows improved survival rates; final patient follow-up in September
- Net loss decreased to $1.6M; expenses reduced by 53% year-over-year
- Company aims to meet NASDAQ listing requirements; exploring non-dilutive funding options
- FDA clearance for Morph DNA product family expected by end of current quarter
- CEO optimistic about end of 2024 and 2025 outlook; partnerships being discussed for key platforms
Last Updated: 2024/08/15, 02:10
Read Full TranscriptCompare BCDA to Peers and Sector
Metrics to compare | BCDA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCDAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −6.0x | −0.6x | |
PEG Ratio | −0.02 | −0.06 | 0.00 | |
Price/Book | 3.6x | 1.8x | 2.6x | |
Price / LTM Sales | 140.1x | 11.5x | 3.2x | |
Upside (Analyst Target) | - | 290.9% | 45.4% | |
Fair Value Upside | Unlock | 20.9% | 7.7% | Unlock |
Analysts' Recommendations
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 25.000
(+1,052.07% Upside)
FAQ
What Is the Biocardia (BCDA) Stock Price Today?
The Biocardia stock price today is 2.17
What Stock Exchange Does Biocardia Trade On?
Biocardia is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Biocardia?
The stock symbol for Biocardia is "BCDA."
What Is the Biocardia Market Cap?
As of today, Biocardia market cap is 9.88M.
What is Biocardia Earnings Per Share?
The Biocardia EPS is -3.92.
From a Technical Analysis Perspective, Is BCDA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.